Drug intelligence / Profile preview

Salivit Immuno

Development stage: Unknown
Lead developer: Logus Pharma
Modality: Small Molecules
Administration: Oral

Overview

Salivit Immuno is a dietary supplement developed by Logus Pharma, specifically formulated to support the immune system. It belongs to the Salivit product line, which focuses on nutritional and metabolic health. The supplement typically contains a combination of micronutrients, including Vitamin C, Vitamin D3, and Zinc, which are essential for the maintenance of normal immune function. It may also include antioxidant compounds like Resveratrol to help protect cells from oxidative stress. As a consumer health product, Salivit Immuno is intended for nutritional support rather than the treatment or prevention of specific medical conditions in a pharmaceutical capacity.

Brand names: Salivit Immuno

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Salivit Immuno.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salivit Immuno.

Explore the full profile